News for NRX Pharmaceuticals Stock (NRXP)

Deadline Monday Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 03/16/22

NRXP FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW

Newsfile Corp • 03/15/22

Monday Deadline Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 03/15/22

DEADLINE NEXT WEEK: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW

Newsfile Corp • 03/15/22

ROSEN, A TOP RANKED LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW

Newsfile Corp • 03/14/22

7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 03/14/22

(NRXP; NRXPW) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading NRx Pharmaceuticals Class Action Lawsuit

Newsfile Corp • 03/14/22

ROSEN, A TOP RANKED FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses Over $100K to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW

PRNewsWire • 03/12/22

ROSEN, A TOP RANKED LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPW

Newsfile Corp • 03/10/22

ROSEN, LEADING INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPW

Newsfile Corp • 03/09/22

NRXP; NRXPW Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NRx Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: March 21, 2022

Business Wire • 03/09/22

NRx Pharmaceuticals Announces Leadership Transition

PRNewsWire • 03/09/22

NRX INVESTOR NEWS: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSE, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPW

Newsfile Corp • 03/07/22

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NRXP; NRXPW

PRNewsWire • 03/05/22

NRXP Investors Have Opportunity to Lead NRx Pharmaceuticals, Inc. Securities Fraud Lawsuit

PRNewsWire • 03/03/22

DEADLINE APPROACHING: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW

PRNewsWire • 03/02/22

NRx Pharmaceuticals: Potential For First In Bipolar Depression Suicidal Ideation Treatment, Along As Covid-19 Play

Seeking Alpha • 02/23/22

NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment

PRNewsWire • 02/15/22

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors

PRNewsWire • 02/14/22

NOTICE: Investors in NRx Pharmaceuticals, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW

Business Wire • 02/12/22

NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine

GlobeNewsWire • 02/11/22

Shareholder Action Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 02/04/22

Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 02/03/22

NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq Rules

PRNewsWire • 02/03/22

Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 02/02/22